BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

460 related articles for article (PubMed ID: 9816329)

  • 1. Cytotoxic and antitumor activity of a recombinant tumor necrosis factor-B1(Fv) fusion protein on LeY antigen-expressing human cancer cells.
    Scherf U; Benhar I; Webber KO; Pastan I; Brinkmann U
    Clin Cancer Res; 1996 Sep; 2(9):1523-31. PubMed ID: 9816329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of recombinant immunotoxins against LeY antigen expressing tumor cells: influence of affinity, size, and stability.
    Bera TK; Pastan I
    Bioconjug Chem; 1998; 9(6):736-43. PubMed ID: 9815167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Construction, production, and characterization of humanized anti-Lewis Y monoclonal antibody 3S193 for targeted immunotherapy of solid tumors.
    Scott AM; Geleick D; Rubira M; Clarke K; Nice EC; Smyth FE; Stockert E; Richards EC; Carr FJ; Harris WJ; Armour KL; Rood J; Kypridis A; Kronina V; Murphy R; Lee FT; Liu Z; Kitamura K; Ritter G; Laughton K; Hoffman E; Burgess AW; Old LJ
    Cancer Res; 2000 Jun; 60(12):3254-61. PubMed ID: 10866319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transfer of chimeric receptor gene made of variable regions of tumor-specific antibody confers anticarbohydrate specificity on T cells.
    Mezzanzanica D; Canevari S; Mazzoni A; Figini M; Colnaghi MI; Waks T; Schindler DG; Eshhar Z
    Cancer Gene Ther; 1998; 5(6):401-7. PubMed ID: 9917095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein.
    Xu X; Clarke P; Szalai G; Shively JE; Williams LE; Shyr Y; Shi E; Primus FJ
    Cancer Res; 2000 Aug; 60(16):4475-84. PubMed ID: 10969795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minimal tumor necrosis factor receptor binding protein: optimum biological activity of a truncated p55 soluble tumor necrosis factor receptor-IgG fusion protein.
    Corcoran AE; Scallon BJ; Trinh H; Chernajovsky Y; Ghrayeb J; Feldmann M
    Eur Cytokine Netw; 1998 Sep; 9(3):255-62. PubMed ID: 9831174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intratumoral vaccination of adenoviruses expressing fusion protein RM4/tumor necrosis factor (TNF)-alpha induces significant tumor regression.
    Wright P; Zheng C; Moyana T; Xiang J
    Cancer Gene Ther; 1998; 5(6):371-9. PubMed ID: 9917092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TNF-Selectokine: a novel prodrug generated for tumor targeting and site-specific activation of tumor necrosis factor.
    Wüest T; Gerlach E; Banerjee D; Gerspach J; Moosmayer D; Pfizenmaier K
    Oncogene; 2002 Jun; 21(27):4257-65. PubMed ID: 12082613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I.
    Sachdev D; Li SL; Hartell JS; Fujita-Yamaguchi Y; Miller JS; Yee D
    Cancer Res; 2003 Feb; 63(3):627-35. PubMed ID: 12566306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha.
    Halin C; Gafner V; Villani ME; Borsi L; Berndt A; Kosmehl H; Zardi L; Neri D
    Cancer Res; 2003 Jun; 63(12):3202-10. PubMed ID: 12810649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human TNF mutants with selective activity on the p55 receptor.
    Van Ostade X; Vandenabeele P; Everaerdt B; Loetscher H; Gentz R; Brockhaus M; Lesslauer W; Tavernier J; Brouckaert P; Fiers W
    Nature; 1993 Jan; 361(6409):266-9. PubMed ID: 8380906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stabilization of a recombinant Fv fragment by base-loop interconnection and V(H)-V(L) permutation.
    Brinkmann U; Di Carlo A; Vasmatzis G; Kurochkina N; Beers R; Lee B; Pastan I
    J Mol Biol; 1997 Apr; 268(1):107-17. PubMed ID: 9149145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective formation of tumor necrosis factor-alpha (TNF) degradation products contributes to TNF mediated cytotoxicity.
    Fruehauf JP; Sinha BK
    Oncol Res; 1992; 4(3):91-101. PubMed ID: 1319775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different types of FCgamma-receptors are involved in anti-Lewis Y antibody induced effector functions in vitro.
    Dettke M; Loibner H
    Br J Cancer; 2000 Jan; 82(2):441-5. PubMed ID: 10646902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. One-step on-column purification and refolding of a single-chain variable fragment (scFv) antibody against tumour necrosis factor alpha.
    Liu M; Wang X; Yin C; Zhang Z; Lin Q; Zhen Y; Huang H
    Biotechnol Appl Biochem; 2006 Mar; 43(Pt 3):137-45. PubMed ID: 16293104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity.
    Nielsen UB; Adams GP; Weiner LM; Marks JD
    Cancer Res; 2000 Nov; 60(22):6434-40. PubMed ID: 11103810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo antitumor activity of a mouse CTL hybridoma expressing chimeric receptors bearing the single chain Fv from HER-2/neu- specific antibody and the gamma-chain from Fc(epsilon) RI.
    Mamalaki A; Gritzapis AD; Kretsovali A; Belimezi M; Papamatheakis J; Perez SA; Papamichail M; Baxevanis CN
    Cancer Immunol Immunother; 2003 Aug; 52(8):513-22. PubMed ID: 12715240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting of interleukin 2 to human ovarian carcinoma by fusion with a single-chain Fv of antifolate receptor antibody.
    Melani C; Figini M; Nicosia D; Luison E; Ramakrishna V; Casorati G; Parmiani G; Eshhar Z; Canevari S; Colombo MP
    Cancer Res; 1998 Sep; 58(18):4146-54. PubMed ID: 9751627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved expression of a soluble single chain antibody fusion protein containing tumor necrosis factor in Escherichia coli.
    Kim S; Cheung LH; Zhang W; Rosenblum MG
    Appl Microbiol Biotechnol; 2007 Nov; 77(1):99-106. PubMed ID: 17703297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted lipid-coated nanoparticles: delivery of tumor necrosis factor-functionalized particles to tumor cells.
    Messerschmidt SK; Musyanovych A; Altvater M; Scheurich P; Pfizenmaier K; Landfester K; Kontermann RE
    J Control Release; 2009 Jul; 137(1):69-77. PubMed ID: 19306900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.